Showing results (511-520 of 5,984) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|May 3, 2015
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLDaniel S Pereira, Claudia I Guevara, Liqing Jin, et al.
Molecular Cancer Therapeutics|May 6, 2015
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in GlioblastomaIra K Gordon, Jie Lu, Christian A Graves, et al.
Molecular Cancer Therapeutics|May 16, 2015
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast CancerRaju Khatri, Preeti Shah, Rupa Guha, et al.
Molecular Cancer Therapeutics|May 2, 2015
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft ModelsChaoxin Hu, Tikva Dadon, Venugopal Chenna, et al.
Molecular Cancer Therapeutics|April 25, 2015
Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle WastingRosamund C Smith, Martin S Cramer, Pamela J Mitchell, et al.
Molecular Cancer Therapeutics|September 5, 2025
Advancing preclinical biology for Ewing Sarcoma: an international effortFilemon S Dela Cruz, Elizabeth A Stewart, Didier Surdez, et al.
Molecular Cancer Therapeutics|August 7, 2016
Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformancePing Chen, Nathan V Lee, Wenyue Hu, et al.
Molecular Cancer Therapeutics|August 7, 2016
Alterative Expression and Localization of Profilin 1/VASPpS157 and Cofilin 1/VASPpS239 Regulates Metastatic Growth and Is Modified by DHA SupplementationMehboob Ali, Kathryn Heyob, Naduparambil K Jacob, et al.
Molecular Cancer Therapeutics|August 11, 2016
Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase SignalosomeMiao Liu, Li-Xing Feng, Peng Sun, et al.
Molecular Cancer Therapeutics|August 11, 2016
FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal ModelCécile Gstalder, Isabelle Ader, Olivier Cuvillier
Pageof 599